Emicizumab: all 26 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance InductionNot yet recruitingNCT07158606Phase 4
• A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruitingNCT06998524Phase 3
• Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsNot yet recruitingNCT06938659Phase 2/3
• Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia ARecruitingNCT06155955Phase 2/3
• A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingNCT06145373Phase 4
• Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia ARecruitingNCT05500807Phase 1
• Hemlibra in Mild Hemophilia ARecruitingNCT04567511Phase 4
• SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingNCT04563520Phase 3
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsActive, not recruitingNCT04431726Phase 3Results posted
• The Hemophilia Inhibitor Eradication TrialTerminatedNCT04303572Phase 3Results posted
• The Hemophilia Inhibitor Prevention TrialTerminatedNCT04303559Phase 3Results posted
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompletedNCT04158648Phase 3Results posted
• HemLibra Prophylaxis in Patients With Hemophilic PseudotumorTerminatedNCT03921294Phase 4Results posted
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese VolunteersCompletedNCT03380780Phase 1Results posted
• Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical ProceduresTerminatedNCT03361137Phase 4Results posted
• Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With InhibitorsCompletedNCT03191799Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia ACompletedNCT03020160Phase 3Results posted
• A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsCompletedNCT02847637Phase 3Results posted
• A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) InhibitorsCompletedNCT02795767Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With InhibitorsCompletedNCT02622321Phase 3Results posted
• Emicizumab in Patients With Acquired Hemophilia AActive, not recruitingNCT05345197Phase 2
• Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory CoastCompletedNCT05279924Not applicable
• A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisActive, not recruitingNCT05181618Phase 4
• POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement TherapiesWithdrawnNCT04690322Phase 4
• Emicizumab in Acquired Hemophilia ACompletedNCT04188639Phase 2

← Emicizumab overview